Dosimetry and pharmacokinetics of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.

ABSTRACT:

Purpose

To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [¹⁷⁷Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs).

Methods

This study was part of a phase I/II trial of [¹⁷⁷Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23.0 Gy for the kidneys and 1.5 Gy for bone marrow. Absorbed dose coefficients (ADCs) were calculated using both patient-specific and model-based dosimetry for some patients.

Result

SUBMITTER: Schurrle SB 

PROVIDER: S-EPMC11178655 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature